138 related articles for article (PubMed ID: 30281370)
1. Atypical Ductal Lesions of the Breast: Criteria, Significance, and Laboratory Updates.
East EG; Carter CS; Kleer CG
Arch Pathol Lab Med; 2018 Oct; 142(10):1182-1185. PubMed ID: 30281370
[TBL] [Abstract][Full Text] [Related]
2. Atypical ductal hyperplasia: update on diagnosis, management, and molecular landscape.
Kader T; Hill P; Rakha EA; Campbell IG; Gorringe KL
Breast Cancer Res; 2018 May; 20(1):39. PubMed ID: 29720211
[TBL] [Abstract][Full Text] [Related]
3. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
4. Type of Architecture, Presence of Punctate Necrosis, and Extent of Involvement in Atypical Ductal Hyperplasia Can Predict the Diagnosis of Breast Carcinoma on Excision: A Clinicopathologic Study of 143 Cases.
Zhang C; Wang EY; Liu F; Ruhul Quddus M; James Sung C
Int J Surg Pathol; 2021 Oct; 29(7):716-721. PubMed ID: 33881947
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic upgrade of atypical ductal hyperplasia of the breast based on evaluation of histopathological features and calcification on core needle biopsy.
Chen LY; Hu J; Tsang JYS; Lee MA; Ni YB; Chan SK; Tse GMK
Histopathology; 2019 Sep; 75(3):320-328. PubMed ID: 31013355
[TBL] [Abstract][Full Text] [Related]
6. Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ.
Tozbikian G; Brogi E; Vallejo CE; Giri D; Murray M; Catalano J; Olcese C; Van Zee KJ; Wen HY
Int J Surg Pathol; 2017 Apr; 25(2):100-107. PubMed ID: 27481892
[TBL] [Abstract][Full Text] [Related]
7. The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification.
Pinder SE; Ellis IO
Breast Cancer Res; 2003; 5(5):254-7. PubMed ID: 12927035
[TBL] [Abstract][Full Text] [Related]
8. Aromatase expression in atypical ductal hyperplasia in women.
Santen RJ; Radisky DC; Degnim A; Frost MH; Vachon CM; Ghosh K; Guestini F; McNamara KM; Sasano H
Breast Cancer Res Treat; 2017 Jun; 163(3):623-629. PubMed ID: 28337664
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with upgrading to malignancy at surgery of atypical ductal hyperplasia diagnosed on core biopsy.
Deshaies I; Provencher L; Jacob S; Côté G; Robert J; Desbiens C; Poirier B; Hogue JC; Vachon E; Diorio C
Breast; 2011 Feb; 20(1):50-5. PubMed ID: 20619647
[TBL] [Abstract][Full Text] [Related]
10. Atypical ductal hyperplasia: Our experience in the management and long term clinical follow-up in 71 patients.
Latronico A; Nicosia L; Faggian A; Abbate F; Penco S; Bozzini A; Cannataci C; Mazzarol G; Cassano E
Breast; 2018 Feb; 37():1-5. PubMed ID: 29032282
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting the under-diagnosis of atypical ductal hyperplasia diagnosed by core needle biopsies - A 10-year retrospective study and review of the literature.
Co M; Kwong A; Shek T
Int J Surg; 2018 Jan; 49():27-31. PubMed ID: 29146271
[TBL] [Abstract][Full Text] [Related]
12. Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy.
Menes TS; Kerlikowske K; Lange J; Jaffer S; Rosenberg R; Miglioretti DL
JAMA Oncol; 2017 Jan; 3(1):36-41. PubMed ID: 27607465
[TBL] [Abstract][Full Text] [Related]
13. Comparative features of carcinoma in situ and atypical ductal hyperplasia of the breast on fine-needle aspiration biopsy specimens.
Abendroth CS; Wang HH; Ducatman BS
Am J Clin Pathol; 1991 Nov; 96(5):654-9. PubMed ID: 1659182
[TBL] [Abstract][Full Text] [Related]
14. Management of high-risk breast lesions diagnosed on core biopsies and experiences from prospective high-risk breast lesion conferences at an academic institution.
Li X; Ma Z; Styblo TM; Arciero CA; Wang H; Cohen MA
Breast Cancer Res Treat; 2021 Feb; 185(3):573-581. PubMed ID: 33068196
[TBL] [Abstract][Full Text] [Related]
15. Expression pattern and methylation of estrogen receptor α in breast intraductal proliferative lesions.
Mao X; Qiao Z; Fan C; Guo A; Yu X; Jin F
Oncol Rep; 2016 Oct; 36(4):1868-74. PubMed ID: 27498697
[TBL] [Abstract][Full Text] [Related]
16. Update on atypical epithelial hyperplasia and ductal carcinoma in situ.
Simpson JF
Pathology; 2009 Jan; 41(1):36-9. PubMed ID: 19089738
[TBL] [Abstract][Full Text] [Related]
17. Estrogen Receptor and Cytokeratin 5 Are Reliable Markers to Separate Usual Ductal Hyperplasia From Atypical Ductal Hyperplasia and Low-Grade Ductal Carcinoma In Situ.
Martinez AP; Cohen C; Hanley KZ; Li XB
Arch Pathol Lab Med; 2016 Jul; 140(7):686-9. PubMed ID: 27116088
[TBL] [Abstract][Full Text] [Related]
18. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies.
Renshaw AA; Gould EW
Pathology; 2016 Jan; 48(1):25-9. PubMed ID: 27020205
[TBL] [Abstract][Full Text] [Related]
19. CD133 expressionand clinicopathologic significance in benign and malignant breast lesions.
Liu TT; Li XF; Wang L; Yang JL
Cancer Biomark; 2020; 28(3):293-299. PubMed ID: 32390595
[TBL] [Abstract][Full Text] [Related]
20. [Breast calcifications with percutaneous vacuum-assisted biopsy diagnosis of malignancy or atypical hyerplasia: correlations with surgical findings].
Piubello Q; Montemezzi S; D'Atri C
Pathologica; 2002 Dec; 94(6):299-305. PubMed ID: 12540993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
